Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.57 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.52 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19861744 | 1.00 | DUT (0.57) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL10521044 | 1.00 | DUT (0.57) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL9218570 | 0.90 | SLC28A1 (0.63) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL21078688 | 0.90 | SLC28A1 (0.63) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2762704 | 0.90 | SLC28A1 (0.63) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL6060488 | 0.90 | SLC28A1 (0.63) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15866629 | 0.88 | DUT (0.58) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL8909630 | 0.88 | DUT (0.57) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL25399050 | 0.87 | DUT (0.56) | DUTP2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL24781265 | 0.87 | DUT (0.56) | DUTP2RY14SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037586-B2 | 4′-phosphate analogs and oligonucleotides comprising the same | DICERNA PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2023183569-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | Molecular Assemblies, Inc. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230064031-A1 | 4'-PHOSPHATE ANALOGS AND OLIGONUCLEOTIDES COMPRISING THE SAME | NOVO NORDISK A/S (DK) | 2023-03-02 | — | — | US | disclosed |
| US-20190177729-A1 | 4'-PHOSPHATE ANALOGS AND OLIGONUCLEOTIDES COMPRISING THE SAME | NOVO NORDISK A/S (DK) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230064031-A1 | 4'-PHOSPHATE ANALOGS AND OLIGONUCLEOTIDES COMPRISING THE SAME | RNGTT, DERA, MTAP | DUT 9/4885P2RY14 1796/4885SLC28A1 564/4885 |
| US-12037586-B2 | 4′-phosphate analogs and oligonucleotides comprising the same | RNGTT, DERA, MTAP | DUT 8/4885P2RY14 1827/4885SLC28A1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.